BACKGROUND: Few studies have examined the risk of multiple or high doses of combined central nervous system (CNS) medication use for recurrent falls in the elderly. The study objective was to evaluate whether multiple- or high-dose CNS medication use in older adults was associated with a higher risk of recurrent (>or=2) falls. METHODS: This longitudinal cohort study included 3,055 participants from the Health, Aging and Body Composition study who were well functioning at baseline. CNS medication use (benzodiazepine and opioid receptor agonists, antipsychotics, antidepressants) was determined annually (except Year 4) during in-person interviews. The number and summated standard daily doses (SDDs; low, medium, and high) of CNS medications were computed. Falls 1 year later were ascertained annually for 5 years. RESULTS: For a period of 5 years, as many as 24.1% of CNS medication users took 2+ agents annually, whereas as no more than 18.9% of CNS medication users took high doses annually (3+ SDDs). Yearly, as many as 9.7% of participants reported recurrent falls. Multivariable Generalized Estimating Equation analyses showed that multiple CNS medication users compared with never users had an increased risk of sustaining 2+ falls (adjusted odds ratio [OR] 1.95; 95% confidence interval [CI] 1.35-2.81). Those taking high (3+) CNS SDDs also exhibited an increased risk of 2+ falls (adjusted OR 2.89; 95% CI 1.96-4.25). CONCLUSIONS: Higher total daily doses of CNS medications were associated with recurrent falls. Further studies are needed to determine the impact of reducing the number of CNS medications and/or dosage on recurrent falls.
BACKGROUND: Few studies have examined the risk of multiple or high doses of combined central nervous system (CNS) medication use for recurrent falls in the elderly. The study objective was to evaluate whether multiple- or high-dose CNS medication use in older adults was associated with a higher risk of recurrent (>or=2) falls. METHODS: This longitudinal cohort study included 3,055 participants from the Health, Aging and Body Composition study who were well functioning at baseline. CNS medication use (benzodiazepine and opioid receptor agonists, antipsychotics, antidepressants) was determined annually (except Year 4) during in-person interviews. The number and summated standard daily doses (SDDs; low, medium, and high) of CNS medications were computed. Falls 1 year later were ascertained annually for 5 years. RESULTS: For a period of 5 years, as many as 24.1% of CNS medication users took 2+ agents annually, whereas as no more than 18.9% of CNS medication users took high doses annually (3+ SDDs). Yearly, as many as 9.7% of participants reported recurrent falls. Multivariable Generalized Estimating Equation analyses showed that multiple CNS medication users compared with never users had an increased risk of sustaining 2+ falls (adjusted odds ratio [OR] 1.95; 95% confidence interval [CI] 1.35-2.81). Those taking high (3+) CNS SDDs also exhibited an increased risk of 2+ falls (adjusted OR 2.89; 95% CI 1.96-4.25). CONCLUSIONS: Higher total daily doses of CNS medications were associated with recurrent falls. Further studies are needed to determine the impact of reducing the number of CNS medications and/or dosage on recurrent falls.
Authors: B M Psaty; T D Koepsell; D Lin; N S Weiss; D S Siscovick; F R Rosendaal; M Pahor; C D Furberg Journal: J Am Geriatr Soc Date: 1999-06 Impact factor: 5.562
Authors: Nathalie van der Velde; Bruno H Ch Stricker; Huib A P Pols; Tischa J M van der Cammen Journal: Br J Clin Pharmacol Date: 2006-08-30 Impact factor: 4.335
Authors: J T Hanlon; R D Horner; K E Schmader; G G Fillenbaum; I K Lewis; W E Wall; L R Landerman; C F Pieper; D G Blazer; H J Cohen Journal: Clin Pharmacol Ther Date: 1998-12 Impact factor: 6.875
Authors: Anne B Newman; Catherine L Haggerty; Stephen B Kritchevsky; Michael C Nevitt; Eleanor M Simonsick Journal: J Gerontol A Biol Sci Med Sci Date: 2003-08 Impact factor: 6.053
Authors: Ulrike Sommeregger; Bernhard Iglseder; Birgit Böhmdorfer; Ursula Benvenuti-Falger; Peter Dovjak; Monika Lechleitner; Ronald Otto; Regina E Roller; Markus Gosch Journal: Wien Med Wochenschr Date: 2010-06
Authors: Zachary A Marcum; Subashan Perera; Anne B Newman; Joshua M Thorpe; Galen E Switzer; Shelly L Gray; Eleanor M Simonsick; Ronald I Shorr; Douglas C Bauer; Nicholas G Castle; Stephanie A Studenski; Joseph T Hanlon Journal: J Gerontol A Biol Sci Med Sci Date: 2015-08-11 Impact factor: 6.053
Authors: Christopher R Carpenter; Manish N Shah; Fredric M Hustey; Kennon Heard; Lowell W Gerson; Douglas K Miller Journal: J Gerontol A Biol Sci Med Sci Date: 2011-04-17 Impact factor: 6.053
Authors: Joseph T Hanlon; Xinhua Zhao; Jennifer G Naples; Sherrie L Aspinall; Subashan Perera; David A Nace; Nicholas G Castle; Susan L Greenspan; Carolyn T Thorpe Journal: J Am Geriatr Soc Date: 2017-02-02 Impact factor: 5.562
Authors: Mary Jo V Pugh; Joseph T Hanlon; Chen-Pin Wang; Todd Semla; Muriel Burk; Megan E Amuan; Ashlei Lowery; Chester B Good; Dan R Berlowitz Journal: J Am Geriatr Soc Date: 2011-08-30 Impact factor: 5.562
Authors: Christine M Ruby; Joseph T Hanlon; Robert M Boudreau; Anne B Newman; Eleanor M Simonsick; Ronald I Shorr; Douglas C Bauer; Neil M Resnick Journal: J Am Geriatr Soc Date: 2010-09 Impact factor: 5.562
Authors: Jennifer G Naples; Zachary A Marcum; Subashan Perera; Shelly L Gray; Anne B Newman; Eleanor M Simonsick; Kristine Yaffe; Ronald I Shorr; Joseph T Hanlon Journal: J Am Geriatr Soc Date: 2015-10 Impact factor: 5.562
Authors: Katherine B Santosa; Yen-Ling Lai; Chad M Brummett; Jeremie D Oliver; Hsou-Mei Hu; Michael J Englesbe; Emilie M Blair; Jennifer F Waljee Journal: J Gen Intern Med Date: 2020-08-03 Impact factor: 5.128